HEMODYNAMIC EFFECTS OF DOBUTAMINE & MILRINONE

多巴酚丁胺的血流动力学效应

• 批准号: 6425942
• 负责人: E MICHAEL GILBERT
• 金额: $ 0.16万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6425942
• 关键词: beta antiadrenergic agent; clinical research; cyclic AMP; dobutamine; drug interactions; drug screening /evaluation; gene expression; heart disorder chemotherapy; heart failure; hemodynamics; human subject; human therapy evaluation; idiopathic dilated cardiomyopathy; pharmacokinetics; phosphodiesterase inhibitors

This is a randomized, double-blind, parallel group, active-controlled trial of eighteen months' duration and a total of 72 patients. The study will be performed at two sites, the University of Utah GCRC and the University of Colorado GCRC. Patients with NYHA class II-IV heart failure due to idiopathic dilated cardiomyopathy will be treated with either bucindolol or metoprolol to determine changes in myocardial gene expression associated with either of these drugs. Changes in gene expression associated with alterations in myocardial function and remodeling are also under study. If bucindolol or metoprolol proves to lower cardiac adrenergic drive, then the relationship of this effect to changes in myocardial gene expression will be defined. If bucindolol or metoprolol lowers activity of the renin-angiotensin system, then the relationship of this effect will also be correlated with changes in myocardial gene expression. Milrinone is a phosphodiesterase inhibitor and the use of this agent will enable the investigators to determine if the effects of bucindolol are enhanced by this drug, suggesting that bucindolol may also act through a cyclic-AMP-dependent mechanism. This study is in its earliest phases but no data are mature enough to report.

这是一项随机，双盲，平行组，有效控制的试验，持续了18个月，共有72例患者。 这项研究将在犹他大学GCRC和科罗拉多大学GCRC大学的两个地点进行。 NYHA II-IV级心力衰竭患者由于特发性扩张性心肌病而导致的患者将用Bucindolol或Metoprolol治疗，以确定与这两种药物相关的心肌基因表达的变化。 与心肌功能改变和重塑有关的基因表达的变化也正在研究中。 如果bucindolol或美托洛尔被证明降低了心脏肾上腺素能驱动，那么将定义这种作用与心肌基因表达变化的关系。 如果bucindolol或美托洛尔降低了肾素 - 血管紧张素系统的活性，那么该作用的关系也将与心肌基因表达的变化相关。 Milrinone是一种磷酸二酯酶抑制剂，该药物的使用将使研究人员能够通过该药物来确定bucindolol的作用是否增强，这表明Bucindolol也可以通过环状AMP依赖机制起作用。这项研究是最早的阶段，但没有足够的数据足以报告。